PDCD1 and myeloid sarcoma: Since MS is a typical autoimmune disorder in the CNS, researchers have also proposed using the programmed cell death protein-1/programmed death ligand-1 (PD-1/PD-L1) pathway to inhibit pathological immune responses and maintain self-tolerance in MS and EAE [62].